We studied the effect of a new hypoglycemic compound dapagliflozin on the functioning of rat liver mitochondria. Dapagliflozin in concentrations of 10-20 μM had no effect on the parameters of respiration and oxidative phosphorylation of rat liver mitochondria. Increasing dapagliflozin concentration to 50 μM led to a significant inhibition of mitochondrial respiration in states 3 and 3UDNP. Dapagliflozin in this concentration significantly reduced calcium retention capacity of rat liver mitochondria. These findings indicate a decline in the resistance of rat liver mitochondria to induction of Ca2+-dependent mitochondrial permeability transition pore. In a concentration of 10 μM, dapagliflozin significantly decreases the rate of H2O2 formation in rat liver mitochondria, which attested to an antioxidant effect of this compound. Possible mitochondrion-related mechanisms of the protective action of dapagliflozin on liver cells are discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Belosludtsev KN, Belosludtseva NV, Mironova GD, Dubinin MV. Mitochondrial Ca2+ transport: mechanisms, molecular structures, and role in cells. Biochemistry (Moscow). 2019;84(6):593-607.
Belosludtsev KN, Belosludtseva NV, Dubinin MV. Diabetes mellitus, mitochondrial dysfunction and Ca2+-dependent permeability transition pore. Int. J. Mol. Sci. 2020;21(18):6559. https://doi.org/10.3390/ijms21186559
Belosludtsev KN, Belosludtseva NV, Kosareva EA, Talanov EY, Gudkov SV, Dubinin MV. Itaconic acid impairs the mitochondrial function by the inhibition of complexes II and IV and induction of the permeability transition pore opening in rat liver mitochondria. Biochimie. 2020;176:150-157. https://doi.org/10.1016/j.biochi.2020.07.011
Belosludtsev KN, Talanov EY, Starinets VS, Agafonov AV, Dubinin MV, Belosludtseva NV. Transport of Ca2+ and Ca2+-dependent permeability transition in rat liver mitochondria under the streptozotocin-induced type I diabet. Cell. 2019;8(9):1014. https://doi.org/10.3390/cells8091014
Cristelo C, Azevedo C, Marques JM, Nunes R, Sarmento B. SARS-CoV-2 and diabetes: New challenges for the disease. Diabetes Res. Clin. Pract. 2020;164:108228. https://doi.org/10.1016/j.diabres.2020.108228
Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin. Pharmacol. 2016;8:61-81. https://doi.org/10.2147/CPAA.S82008
FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). FDA Drug Safety Communication, 2016. URL: https://www.fda.gov/Drugs/DrugSafety/ucm505860.htm
Fusco S, Garasto S, Corsonello A, Vena S, Mari V, Gareri P, Ruotolo G, Luciani F, Roncone A, Maggio M, Lattanzio F. Medication-induced nephrotoxicity in older patients. Curr. Drug Metab. 2016;17(6):608-625. https://doi.org/10.2174/1389200217666160406115959
Lahnwong S, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, Chattipakorn SC, Chattipakorn N. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc. Diabetol. 2020;19(1):91. https://doi.org/10.1186/s12933-020-01066-9
Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic. Biol. Med. 2017;104:298-310. https://doi.org/10.1016/j.freeradbiomed.2017.01.03
Mamidi RN, Proctor J, De Jonghe S, Feyen B, Moesen E, Vinken P, Ma JY, Bryant S, Snook S, Louden C, Lammens G, Ways K, Kelley MF, Johnson MD. Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin. Chem. Biol. Interact. 2014;221:109-118. https://doi.org/10.1016/j.cbi.2014.08.001
Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2020;16(10):556-577. https://doi.org/10.1038/s41574-020-0392-2
Secker PF, Beneke S, Schlichenmaier N, Delp J, Gutbier S, Leist M, Dietrich DR. Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Cell Death Dis. 2018;9(2):226. https://doi.org/10.1038/s41419-018-0273-y
Winer N, Sowers JR. Epidemiology of diabetes. J. Clin. Pharmacol. 2004;44(4):397-405. https://doi.org/10.1177/0091270004263017
Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPKmediated inhibition of mitochondrial fission. Redox Biol. 2018;15:335-346. https://doi.org/10.1016/j.redox.2017.12.019
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 171, No. 5, pp. 572-576, May, 2021
Rights and permissions
About this article
Cite this article
Belosludtseva, N.V., Starinets, V.S. & Belosludtsev, K.N. Effect of Dapagliflozin on the Functioning of Rat Liver Mitochondria In Vitro. Bull Exp Biol Med 171, 601–605 (2021). https://doi.org/10.1007/s10517-021-05277-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-021-05277-2